Neuropsychiatrist Albino Oliveira-Maia of the Champalimaud Foundation is utilizing psychedelic substances in the treatment of severe depression and other mental health disorders. This innovative approach raises ethical questions regarding the manipulation of brain function and acceptable treatment boundaries. Oliveira-Maia’s work suggests potential benefits for patients unresponsive to traditional therapies. The use of psychedelics is currently focused on cases of profound, treatment-resistant depression. While promising, the practice necessitates careful consideration of ethical implications related to altering brain activity. This represents a developing area of mental healthcare, exploring novel treatments for challenging conditions. Further research and ethical debate are expected as this field progresses.